It is a very cold February night in Berlin. As the snow falls and attendees of the Berlin Film Festival bundle up, Timothée ...

AbbVie’s two immunology mainstays, Rinvoq and Skyrizi, which often took the top two spending spots throughout 2024, fell to third and fourth, respectively, this time around. With $42.5 million ...

In a carbon copy of 2023’s results, the 2024 list features AbbVie’s Skyrizi and Rinvoq in the top two spots, followed by yet another immunology giant, Sanofi and Regeneron’s Dupixent ...

Sales of its immune-disease therapy Humira were down 49% globally at $1.68 billion, and declined even more steeply in the U.S. The drug was previously AbbVie's top seller but now faces competition ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

This actress made her Bollywood debut at the tender age of three and went on to work with some of the top actors in the industry. She starred alongside renowned names like Manoj Bajpayee ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy over Humira and other currently leading treatment options, which should support combined annual sales of ...

Entertainment Weekly's Oscars expert, 'RuPaul's Drag Race' beat reporter, host of 'Quick Drag' Twitter Spaces, and cohost of 'EW's BINGE' podcast. Almost all of the drag content on this site is my ...

44,097 people played the daily Crossword recently. Can you solve it faster than others?44,097 people played the daily Crossword recently. Can you solve it faster than others? Nvidia Stock Is Doing ...

These 2 Dividend Stocks Offer Yields Above 6%. Want Decades of Passive Income? 2 Top Dividend Stocks to Buy in 2025 and Hold Forever.